Cytrellis, a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for patients, today announced the closing of a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors ARCH Venture Partners and PFM Health Sciences. Proceeds will be utilized to develop the company's commercial infrastructure as well as support additional clinical research, product development, and manufacturing.

Cytrellis Biosystems, Inc. has developed a novel class of aesthetic devices designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading dermatologists and plastic surgeons to develop unique product solutions which emphasize safety, clinical results and improved quality of life.